Table 1.
Baseline clinical characteristics
| All patients (n = 208) | Thyroid AE (n = 41) | No thyroid AE (n = 167) | p value | ||
|---|---|---|---|---|---|
| Age, median (IQR), years | 61.0 (54.3–68.0) | 62.0 (54.0–67.5) | 61.0 (54.0–68.0) | 0.822 | |
| Male sex, n (%) | 179 (86.1) | 33 (80.5) | 146 (87.4) | 0.251 | |
| ECOG performance status, n (%) | |||||
| 0 | 97 (46.6) | 19 (46.3) | 78 (46.7) | 0.967 | |
| 1 | 111 (53.4) | 22 (53.7) | 89 (53.3) | ||
| Child-Pugh classification, n (%) | |||||
| A | 169 (81.3) | 35 (85.4) | 134 (80.2) | 0.451 | |
| B | 39 (18.8) | 6 (14.6) | 33 (19.8) | ||
| Barcelona clinical liver cancer stage, n (%) | |||||
| B | 38 (18.3) | 9 (22.0) | 29 (17.4) | 0.496 | |
| C | 170 (81.7) | 32 (78.0) | 138 (82.6) | ||
| AFP ≥400 ng/mL, n (%) | 72 (34.6) | 9 (22.0) | 63 (37.7) | 0.057 | |
| NLR, median (IQR) | 2.6 (1.7–4.2) | 2.1 (1.6–3.5) | 2.8 (1.8–4.2) | 0.040 | |
| Presence of MVI, n (%) | 84 (40.4) | 17 (41.5) | 67 (40.1) | 0.875 | |
| Presence of extrahepatic spread, n (%) | 127 (61.1) | 23 (56.1) | 104 (62.3) | 0.467 | |
| Etiology of HCC, n (%) | |||||
| Hepatitis B | 143 (68.8) | 28 (68.3) | 115 (68.9) | 0.663 | |
| Hepatitis C | 13 (6.3) | 1 (2.4) | 12 (7.2) | ||
| Alcohol | 25 (12.0) | 6 (14.6) | 19 (11.4) | ||
| Other or unknown | 27 (13.0) | 6 (14.6) | 21 (12.6) | ||
| Prior local therapy for HCC, n (%) | 145 (69.7) | 32 (78.0) | 113 (67.7) | 0.195 | |
Significant p values in bold.
AE, adverse event; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; MVI, macrovascular invasion.